Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Delfi Diagnostics Inc.
Cook Group Incorporated
Regeneron Pharmaceuticals
AstraZeneca
Hoffmann-La Roche
Immuneering Corporation
Imugene Limited
Eurofarma Laboratorios S.A.
Creative Biosciences (Guangzhou) Co., Ltd.
Boston Scientific Corporation
Taproot Health
Astellas Pharma Inc
AstraZeneca
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Imunon
Advaxis, Inc.
Morphotek
Mural Oncology, Inc
ZielBio, Inc.
Daiichi Sankyo
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Cantargia AB
Celgene
Karyopharm Therapeutics Inc
Novartis
Daiichi Sankyo
Checkpoint Therapeutics, Inc.
Novartis
Daiichi Sankyo
Organon and Co
Takeda
Novartis
Tracon Pharmaceuticals Inc.
Endocyte
Endocyte
Novartis
Quest PharmaTech Inc.
Acrotech Biopharma Inc.
Celgene
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Janssen Research & Development, LLC
Clovis Oncology, Inc.
Boehringer Ingelheim
Merck KGaA, Darmstadt, Germany
ValiSeek Limited